Physician profile
Carmen E Landaverde
NPI 1902093263
$188,733.39
in general payments reported to CMS, 2019-2025
27 companies · $104K in 2025
The $104K reported for 2025 was more than what 94% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $11.95 · 2021: $2,838 · 2022: $18K · 2023: $16K · 2024: $47K · 2025: $104K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $34K · Consulting Fee: $25K · Travel and Lodging: $17K · Food and Beverage: $11K · Honoraria: $3,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,338.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $33,750.00 |
| Consulting Fee | $24,700.00 |
| Travel and Lodging | $16,959.25 |
| Food and Beverage | $11,152.46 |
| Honoraria | $3,150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $63,957.76 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $53,435.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $32,711.02 | 2021-2025 | Livdelzi, Epclusa |
| Ipsen Biopharmaceuticals, INC | $19,109.87 | 2023-2025 | Iqirvo, Bylvay |
| Mirum Pharmaceuticals, INC. | $11,220.71 | 2024-2025 | Livmarli |
| Boston Scientific Corporation | $2,952.32 | 2019-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Albireo Pharma, INC. | $2,508.61 | 2022-2023 | Bylvay |
| Novo Nordisk INC | $1,253.09 | 2021-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $591.20 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $170.36 | 2023-2025 | Imfinzi |
| Orphalan INC | $141.36 | 2024-2025 | Cuvrior |
| Histosonics, INC. | $140.35 | 2025 | |
| Dova Pharmaceuticals | $129.52 | 2019 | |
| Horizon Therapeutics Plc | $120.13 | 2023 | Krystexxa |
| Exelixis INC. | $74.48 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $65.77 | 2022-2024 | Terlivaz |
| Eton Pharmaceuticals, INC. | $44.91 | 2025 | Galzin, Carglumic Acid, Nitisinone |
| Takeda Pharmaceuticals U.S.A., INC. | $30.33 | 2024 | Vpriv |
| Abbvie INC. | $27.41 | 2023 | |
| Alexion Pharmaceuticals, INC. | $26.69 | 2019 | |
| Travere Therapeutics, INC. | $22.46 | 2019-2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Landaverde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.